GlaxoSmithKline (GSK) has agreed to sell all of its gene therapy assets to Orchard Therapeutics in return for 19.9 percent equity in the buyer. The sale is of no surprise to analysts as GSK has been slow to achieve commercial success in the emerging field. As part of the deal, GSK will also receive payments and royalties on sales of the therapies that Orchard is purchasing.
GlaxoSmithKline (GSK) has agreed to sell all of its gene therapy assets to Orchard Therapeutics in return for 19.9% equity in the buyer. The sale is of no surprise to analysts as GSK has been slow to achieve commercial success in the emerging field. As part of the deal, GSK will also receive payments and royalties on sales of the therapies that Orchard is purchasing.